September 10, 2019 Licensing, IP, and Legal PR/Corporate Product Launch

Roche presents new OCREVUS (ocrelizumab) biomarker data that increase understanding of disease progression in multiple sclerosis at ECTRIMS

Basel, 10 September 2019 Roche presents new OCREVUS (ocrelizumab) biomarker data that increase understanding of disease progression in multiple sclerosis at ECTRIMS Blood neurofilament light chain (NfL) levels were significantly lowered following OCREVUS treatment in analyses of Phase III studies in RMS and PPMS New data show NfL may be a biomarker for predicting future... Read more

September 6, 2019 Uncategorized

European Commission approves Roche’s Tecentriq in combination with chemotherapy for the initial treatment of people with extensive-stage small cell lung cancer

Basel, 06 September 2019 European Commission approves Roche’s Tecentriq in combination with chemotherapy for the initial treatment of people with extensive-stage small cell lung cancer Tecentriq in combination with chemotherapy (carboplatin and etoposide) is the first and only cancer immunotherapy approved by the European Medicines Agency for the initial treatment of extensive-stage small cell lung... Read more

September 6, 2019 Clinical Research/Diagn. Product Launch

European Commission approves Roche’s new Tecentriq-based combination therapy as an initial treatment for most common form of advanced lung cancer

Basel, 06 September 2019 European Commission approves Roche’s new Tecentriq-based combination therapy as an initial treatment for most common form of advanced lung cancer The approval of the new Tecentriq-based combination expands treatment options for people across Europe affected by non-squamous non-small cell lung cancer (NSCLC) Decision based on data showing that the Tecentriq plus... Read more

September 5, 2019 Clinical Research/Diagn.

New Study Reinforces Clinical Utility of Combining Tumor Mutation Burden and PD-L1 as Predictive Biomarkers for Immune Checkpoint Inhibitor Therapy

New Study Reinforces Clinical Utility of Combining Tumor Mutation Burden and PD-L1 as Predictive Biomarkers for Immune Checkpoint Inhibitor Therapy CARLSBAD, Calif., Sept. 5, 2019 /PRNewswire/ — Tumor mutational burden (TMB) has recently emerged as a potential biomarker to help guide ICI (immune checkpoint inhibitor) therapy. A new study published in The Journal of Pathology further establishes TMB’s... Read more

September 4, 2019 PR/Corporate

Roche to present pivotal data for satralizumab in neuromyelitis optica spectrum disorder and six-year OCREVUS data in multiple sclerosis at ECTRIMS

Basel, 04 September 2019 Roche to present pivotal data for satralizumab in neuromyelitis optica spectrum disorder and six-year OCREVUS data in multiple sclerosis at ECTRIMS Investigational medicine satralizumab significantly reduces the risk of relapse in pivotal SAkuraStar monotherapy study for neuromyelitis optica spectrum disorder New data provide insights into neurofilament light chain levels as a... Read more

September 3, 2019 Atomic Spectroscopy Clinical Research/Diagn.

Roche and Spark Therapeutics, Inc. announce extension of tender offer for shares of Spark Therapeutics, Inc.

Basel, 03 September 2019 Roche and Spark Therapeutics, Inc. announce extension of tender offer for shares of Spark Therapeutics, Inc. Roche (SIX: RO, ROG; OTCQX: RHHBY) and Spark Therapeutics, Inc. (NASDAQ: ONCE) (“Spark”) today announced that Roche has extended the offering period of its previously announced tender offer to purchase all of the outstanding shares... Read more

September 2, 2019 Bio/Pharma/CRO PR/Corporate

Positive phase III results show Xofluza reduces risk of developing flu after contact with an infected person by 86%

Basel, 02 September 2019 Positive phase III results show Xofluza reduces risk of developing flu after contact with an infected person by 86% BLOCKSTONE study reaches primary endpoint of fewer people testing positive for flu, with fever and at least one respiratory symptom, when treated with Xofluza versus placebo Xofluza may represent an important and... Read more

September 2, 2019 Bio/Pharma/CRO PR/Corporate

Roche presents positive phase III study results for one-dose Xofluza in children with flu

Basel, 02 September 2019 Roche presents positive phase III study results for one-dose Xofluza in children with flu Phase III MINISTONE-2 data are consistent with known safety profile of Xofluza (baloxavir marboxil) in children and show comparable efficacy to oseltamivir Xofluza was administered as a new one-dose oral suspension, a potentially more convenient treatment option... Read more

August 29, 2019 Clinical Research/Diagn. Licensing, IP, and Legal Product Launch

Roche launches VENTANA PD-L1 (SP142) Assay in CE markets as first companion diagnostic to identify triple-negative breast cancer patients eligible for treatment with Tecentriq

Basel, 29 August 2019 Roche launches VENTANA PD-L1 (SP142) Assay in CE markets as first companion diagnostic to identify triple-negative breast cancer patients eligible for treatment with Tecentriq This launch represents an important step in Roche’s personalised healthcare strategy to fit treatments to patients who can benefit most from a specific medicine Each year 300,000... Read more

August 29, 2019 Licensing, IP, and Legal

European Commission approves Roche’s Tecentriq in combination with Abraxane for people with PD-L1-positive, metastatic triple-negative breast cancer

Basel, 29 August 2019 European Commission approves Roche’s Tecentriq in combination with Abraxane for people with PD-L1-positive, metastatic triple-negative breast cancer The Tecentriq combination marks the first cancer immunotherapy regimen to be available in Europe for triple-negative breast cancer – an aggressive and difficult-to-treat disease Approval based on the Phase III IMpassion130 study, which showed... Read more